Oral anticoagulant treatment (OAT) is strongly recommended for the prevention of ischemic stroke or systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and additive risk factors for cardio-embolic events. Evidence from randomized controlled trials (RCTs) [1] and observational studies consistently demonstrated a superior net clinical benefit of direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) [2,3] although such a superiority may differ among DOACs [4,5].
